

DCF Psychotropic Medication Advisory Committee
MINUTES

September 5, 2014 1:00 PM

Albert J. Solnit Children's Center, Middletown, CT.

Present: Jacqueline Harris, M.D., Chris Malinowski, APRN; Amy Veivia, Pharm. D.; David S. Aresco, Pharmacist, Patricia Cables APRN; Debra Brown, M.D.; Lee Combrick-Graham, M.D.; Maureen Evelyn, Parent Advocate; Jason Gott, Pharmacist; Brian Keyes, M.D.; Renu Kothari, M.D.; Chris Malinowski, APRN; Sherrie Sharp, M.D.; Miranda Lindsay, Pharm.D. Candidate.

1. Call to order: Dr. Harris called the meeting to order at 110pm.
2. Set date/time of next meeting: The next meeting is scheduled for October 3, 2014 from 1pm – 2:30pm; Solnit Center AB conference room.
3. Minutes: The minutes of the June 2014 meeting were reviewed and approved with minor changes.
4. Announcements:
 - Introductions were done.
 - Medication prior authorization can now be initiated and the status checked on line @ CTDSMAP.com. This is done via a secure provider portal. This information was sent to all providers via a provider bulletin. The bulletin etc. will be sent to all PMAC members.
 - PA13-178: This is legislation that will require DCF to develop a draft document for child mental health services. This document was published 05 September 2014 (today). Comment from PMAC members is requested. A link to review the document and provide comment will be sent to all MAC members. Responses/comments must be done by 12 September 2014.
 - i. Thanks to PMAC members who participated in the development of this draft document. PMAC member input was instrumental in this process.
5. Old Business:

Review for addition to the approved drug list:

 - Cymbalta: A drug monograph was distributed and discussed. A large study in children showed non superior to placebo at 10 weeks. PMAC voted unanimously to not add this medication to the approved drug list.
 - Pristiq: A drug monograph was distributed and discussed. There is 1 ongoing trial in phase III with results expected in 2017. There is 1 trial that has published the raw data but analysis of this data is pending. Noted there is no efficacy data published at this time.

Venlafaxine safety and efficacy was discussed. Possible issues with withdrawal were discussed. PMAC voted unanimously to not add this medication at this time. Pristiq will be considered again with the routine annual review of this class of medication.

- Paxil: A drug monograph was distributed and discussed. Noted that CMCU usually processes requests to continue this medication and rarely are there requests to start this medication. Noted there is no new compelling evidence regarding the safety and efficacy of this medication in children and/or adolescents. PMAC voted unanimously to not add this medication.
- PMAC discussed the need for standardizing the criteria regarding safety and efficacy in the drug approval process.

6. New Business: Annual plan for PMAC.

- The draft plan overview distributed as part of the meeting announcement was distributed and discussed in detail.
- ADR reporting: current system discussed. PMAC agreed that this should be a project for the upcoming year. Noted that an ADR subcommittee had met and has developed several recommendations. A brief description of a 2 level system was presented. Serious ADR's to be reported in detail via CMCU. Routine to be reported in aggregate looking for trends. This project will begin in earnest with the Oct/Nov PMAC meetings.
- Racial parity: The Commissioner is requiring "across the board equality". There is currently a disparity regarding the number of medications prescribed in addition to other disparity issues. Racial demographics should be included in reporting data whenever possible. The goal of CMCU is to reduce disparity issues relating to medication use over time. It was noted that there may be a need to begin inquiring about other therapies/treatments also especially as they may relate to reducing medication use. Noted that community racial ratios should be considered when addressing this issue. Noted CMCU has requested this data from the central office to help ensure fair comparisons are done. PMAC agreed that this should be a project for the upcoming year.
- Drug use Evaluation (DUE): PMAC agreed that this should be a continuing project for the upcoming year. The next DUE will be antipsychotic use.
 - Preliminary data on antipsychotic use was distributed and discussed in detail. Noted the data was on committed children only. Noted that the Office of Research and Evaluation (ORE) available as a resource to assist with data drill down. For example ORE can assist with determining an adequate sample size.

- It was noted that the data does not include diagnosis or the condition being treated (mood, insomnia, etc.). This is due to this data not being readily available at this time.
- Noted CMCU data only includes medications that have been approved for use.
- Noted foster care data will be included.
- There was a discussion regarding how to present the data: for example raw data vs. charts. Noted that a gender category was added July 14, 2014 so this information is not consistently available prior to that date.
- A suggestion was made to use the presentation of antidepressant DUE data as a template or this DUE.
- Drill down data points: recommend:
 - Polypharmacy – 2 or more antipsychotics concurrently except for cross tapers.
 - Children on antipsychotics that have not yet reached their 6th birthday.

7. Adjournment: 225pm.

Respectfully submitted:

David S. Aresco